

Jonathan S Zager

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5691455/publications.pdf>

Version: 2024-02-01

265
papers

10,193
citations

41258

49
h-index

42291

92
g-index

268
all docs

268
docs citations

268
times ranked

10043
citing authors

#	ARTICLE	IF	CITATIONS
1	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2780-2788.	0.8	1,988
2	Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. <i>New England Journal of Medicine</i> , 2017, 376, 2211-2222.	13.9	1,087
3	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. <i>Annals of Surgical Oncology</i> , 2016, 23, 4169-4177.	0.7	236
4	Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4387-4393.	0.8	204
5	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 399-413.	0.8	190
6	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	5.1	155
7	Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. <i>European Journal of Cancer</i> , 2017, 75, 47-55.	1.3	145
8	Combined Analysis of Phase III Trials Evaluating [^{99m} Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 680-688.	0.7	138
9	Dermatofibrosarcoma Protuberans: How Wide Should We Resect?. <i>Annals of Surgical Oncology</i> , 2010, 17, 2112-2118.	0.7	134
10	A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US. <i>Journal of the American College of Surgeons</i> , 2009, 208, 706-715.	0.2	132
11	Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. <i>Annals of Surgical Oncology</i> , 2018, 25, 356-377.	0.7	130
12	Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 1309-1319.	0.7	117
13	Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. <i>BMC Cancer</i> , 2018, 18, 130.	1.1	117
14	Natural Ceramide Reverses Fas Resistance of Acid Sphingomyelinase $\alpha\alpha'$ Hepatocytes. <i>Journal of Biological Chemistry</i> , 2001, 276, 8297-8305.	1.6	114
15	Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. <i>Cancer Gene Therapy</i> , 2002, 9, 935-945.	2.2	89
16	Surgical Management of Melanoma-In-Situ Using a Staged Marginal and Central Excision Technique. <i>Annals of Surgical Oncology</i> , 2009, 16, 1526-1536.	0.7	88
17	Effects of Preexisting Immunity on the Response to Herpes Simplex-Based Oncolytic Viral Therapy. <i>Human Gene Therapy</i> , 2000, 11, 2465-2472.	1.4	84
18	Pelvic Exenteration Affords Safe and Durable Treatment for Locally Advanced Rectal Carcinoma. <i>Annals of Surgical Oncology</i> , 2007, 14, 1870-1877.	0.7	83

#	ARTICLE	IF	CITATIONS
19	Routine Omission of Sentinel Lymph Node Biopsy for Merkel Cell Carcinoma ≤ 1 cm Is Not Justified. <i>Journal of Clinical Oncology</i> , 2010, 28, e7-e7.	0.8	80
20	Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. <i>Cancer</i> , 2014, 120, 781-789.	2.0	79
21	Radiation Therapy is Associated with Improved Outcomes in Merkel Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 3572-3578.	0.7	77
22	Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. <i>Cancer</i> , 2018, 124, 297-305.	2.0	76
23	Clinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience. <i>PLoS ONE</i> , 2015, 10, e0140362.	1.1	76
24	Shave Biopsy Is a Safe and Accurate Method for the Initial Evaluation of Melanoma. <i>Journal of the American College of Surgeons</i> , 2011, 212, 454-460.	0.2	74
25	Prospective Multicenter Phase II Trial of Systemic ADH-1 in Combination With Melphalan via Isolated Limb Infusion in Patients With Advanced Extremity Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1210-1215.	0.8	73
26	Pediatric melanoma: Analysis of an international registry. <i>Cancer</i> , 2013, 119, 4012-4019.	2.0	71
27	Sentinel Lymph Node Biopsy for Melanoma: Indications and Rationale. <i>Cancer Control</i> , 2009, 16, 234-239.	0.7	69
28	Current Diagnosis and Management of Retroperitoneal Sarcoma. <i>Cancer Control</i> , 2011, 18, 177-187.	0.7	67
29	BRAF and MEK inhibition in melanoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 559-570.	1.0	67
30	Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 3960-3965.	0.7	67
31	Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 44.	1.3	67
32	The Unique Clinical Characteristics of Melanoma Diagnosed in Children. <i>Annals of Surgical Oncology</i> , 2012, 19, 3888-3895.	0.7	66
33	Cutaneous Angiosarcoma: A Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 3391-3397.	0.7	66
34	Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. <i>Journal of Surgical Oncology</i> , 2018, 117, 1170-1178.	0.8	65
35	Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience. <i>Journal of the American College of Surgeons</i> , 2019, 228, 644-649.	0.2	65
36	Sentinel Node Biopsy is Indicated for Thin Melanomas ≤ 0.76 mm. <i>Annals of Surgical Oncology</i> , 2012, 19, 3335-3342.	0.7	64

#	ARTICLE	IF	CITATIONS
37	Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 893-899.	1.5	64
38	Interleukin 12 Secretion Enhances Antitumor Efficacy of Oncolytic Herpes Simplex Viral Therapy for Colorectal Cancer. Annals of Surgery, 2001, 233, 819-826.	2.1	63
39	Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a β 1 34.5 deleted oncolytic herpes virus (G207). FASEB Journal, 2004, 18, 1001-1003.	0.2	62
40	Pathology Review of Thin Melanoma and Melanoma in Situ in a Multidisciplinary Melanoma Clinic: Impact on Treatment Decisions. Journal of Clinical Oncology, 2010, 28, 481-486.	0.8	62
41	Both tumor depth and diameter are predictive of sentinel lymph node status and survival in μ erkel cell carcinoma. Cancer, 2015, 121, 3252-3260.	2.0	62
42	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. Expert Opinion on Drug Safety, 2019, 18, 381-392.	1.0	62
43	Telomere length and risk of melanoma, squamous cell carcinoma, and basal cell carcinoma. Cancer Epidemiology, 2013, 37, 434-439.	0.8	59
44	Merkel Cell Carcinoma of Unknown Primary Origin. Annals of Surgical Oncology, 2012, 19, 2360-2366.	0.7	58
45	Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer, 2014, 120, 1369-1378.	2.0	58
46	Recent developments in the medical and surgical treatment of melanoma. Ca-A Cancer Journal for Clinicians, 2014, 64, 171-185.	157.7	56
47	Predictive Factors of Regional Toxicity and Serum Creatine Phosphokinase Levels After Isolated Limb Infusion for Melanoma: A Multi-Institutional Analysis. Annals of Surgical Oncology, 2009, 16, 2570-2578.	0.7	55
48	Therapy for Unresectable Recurrent and In-Transit Extremity Melanoma. Cancer Control, 2008, 15, 225-232.	0.7	54
49	Jejunal Diverticulosis: A Rare Entity with Multiple Presentations, a Series of Cases. Digestive Surgery, 2000, 17, 643-645.	0.6	51
50	Limiting the Morbidity of Inguinal Lymphadenectomy for Metastatic Melanoma. Cancer Control, 2009, 16, 240-247.	0.7	51
51	Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. Annals of Surgical Oncology, 2016, 23, 2330-2335.	0.7	49
52	Toxicities associated with hyperthermic isolated limb perfusion and isolated limb infusion in the treatment of melanoma and sarcoma. International Journal of Hyperthermia, 2008, 24, 275-289.	1.1	48
53	Desmoplastic Melanoma: Is There a Role for Sentinel Lymph Node Biopsy?. Annals of Surgical Oncology, 2013, 20, 2345-2351.	0.7	46
54	Cutaneous Leiomyosarcoma: Treatment and Outcomes with a Standardized Margin of Resection. Cancer Control, 2013, 20, 307-312.	0.7	46

#	ARTICLE	IF	CITATIONS
55	Who Is to Blame for False-Negative Sentinel Node Biopsies in Melanoma?. <i>Annals of Surgical Oncology</i> , 2010, 17, 670-673.	0.7	45
56	Isolated Limb Perfusion and Infusion for Extremity Soft Tissue Sarcoma: A Contemporary Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2017, 24, 3803-3810.	0.7	45
57	Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: A single institution experience. <i>Journal of Surgical Oncology</i> , 2014, 109, 434-439.	0.8	43
58	Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. <i>Cancer</i> , 2015, 121, 1628-1636.	2.0	43
59	Occult Primary. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1358-1395.	2.3	41
60	Isolated Limb Infusion in a Series of Over 100 Infusions: A Single-Center Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 1121-1127.	0.7	41
61	Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9081-9089.	1.0	41
62	A Multi-institutional Experience of Repeat Regional Chemotherapy for Recurrent Melanoma of Extremities. <i>Annals of Surgical Oncology</i> , 2012, 19, 1637-1643.	0.7	40
63	Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma. <i>EBioMedicine</i> , 2019, 47, 89-97.	2.7	39
64	Limb Preservation With Isolated Limb Infusion for Locally Advanced Nonmelanoma Cutaneous and Soft-Tissue Malignant Neoplasms. <i>Archives of Surgery</i> , 2011, 146, 870.	2.3	38
65	Resection Margins in Merkel Cell Carcinoma: Is a 1-cm Margin Wide Enough?. <i>Annals of Surgical Oncology</i> , 2018, 25, 3334-3340.	0.7	38
66	Intussusception: An Uncommon Cause of Postoperative Small Bowel Obstruction after Gastric Bypass. <i>Obesity Surgery</i> , 2004, 14, 116-119.	1.1	37
67	Active surveillance of patients who have sentinel node positive melanoma: An international, multi-institution evaluation of adoption and early outcomes after the Multicenter Selective Lymphadenectomy Trial II (MSLT2). <i>Cancer</i> , 2021, 127, 2251-2261.	2.0	37
68	A Multicenter Prospective Evaluation of the Clinical Utility of F-18 FDG-PET/CT in Patients With AJCC Stage IIIB or IIIC Extremity Melanoma. <i>Annals of Surgery</i> , 2012, 256, 350-356.	2.1	36
69	Burden of Disease Predicts Response to Isolated Limb Infusion with Melphalan and Actinomycin D in Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 482-488.	0.7	36
70	Management of Sentinel Lymph Node Metastasis in Merkel Cell Carcinoma: Completion Lymphadenectomy, Radiation, or Both?. <i>Annals of Surgical Oncology</i> , 2019, 26, 379-385.	0.7	36
71	Developments in Intralesional Therapy for Metastatic Melanoma. <i>Cancer Control</i> , 2016, 23, 12-20.	0.7	36
72	Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 2131-2146.	3.2	36

#	ARTICLE	IF	CITATIONS
73	Long-term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 2486-2494.	0.7	35
74	Merkel Cell Carcinoma: Pathologic Findings and Prognostic Factors. <i>Current Problems in Cancer</i> , 2010, 34, 47-64.	1.0	34
75	Preoperative Ultrasound is Not Useful for Identifying Nodal Metastasis in Melanoma Patients Undergoing Sentinel Node Biopsy: Preoperative Ultrasound in Clinically Node-Negative Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 1100-1106.	0.7	33
76	Treatment Options for Limited or Symptomatic Metastatic Melanoma. <i>Cancer Control</i> , 2008, 15, 239-247.	0.7	32
77	Progression of cutaneous melanoma: implications for treatment. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 775-796.	1.7	32
78	Isolated Limb Infusion: A Single-Center Experience with Over 200 Infusions. <i>Annals of Surgical Oncology</i> , 2017, 24, 3842-3849.	0.7	32
79	Sentinel node biopsy in atypical melanocytic neoplasms in childhood: a single institution experience in 24 patients. <i>Journal of Cutaneous Pathology</i> , 2012, 39, 331-336.	0.7	29
80	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. <i>Cancer</i> , 2019, 125, 18-44.	2.0	29
81	Neoadjuvant Interleukin-12 Immunogene Therapy Protects Against Cancer Recurrence After Liver Resection in an Animal Model. <i>Annals of Surgery</i> , 2000, 231, 762-771.	2.1	28
82	Controversies in the Evaluation and Management of Atypical Melanocytic Proliferations in Children, Adolescents, and Young Adults. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 679-686.	2.3	28
83	Identifying Risk Factors Using a Skin Cancer Screening Program. <i>Cancer Control</i> , 2013, 20, 248-254.	0.7	27
84	Locoregional Therapies in Melanoma. <i>Surgical Clinics of North America</i> , 2014, 94, 1003-1015.	0.5	27
85	Occult Primary, Version 3.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 969-974.	2.3	27
86	Hepatic Progression-free and Overall Survival After Regional Therapy to the Liver for Metastatic Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 747-753.	0.6	27
87	Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma. <i>PLoS ONE</i> , 2015, 10, e0119716.	1.1	27
88	Replication-competent herpes virus NV1020 as direct treatment of pleural cancer in a rat model. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2002, 124, 123-129.	0.4	26
89	What is the Significance of the In Transit or Interval Sentinel Node in Melanoma?. <i>Annals of Surgical Oncology</i> , 2011, 18, 3232-3234.	0.7	26
90	The role of radical amputations for extremity tumors: A single institution experience and review of the literature. <i>Journal of Surgical Oncology</i> , 2012, 105, 149-155.	0.8	26

#	ARTICLE	IF	CITATIONS
91	Comparison of Single-Photon Emission Computed Tomography (SPECT/CT) and Conventional Planar Lymphoscintigraphy for Sentinel Node Localization in Patients with Cutaneous Malignancies. <i>Annals of Surgical Oncology</i> , 2017, 24, 355-361.	0.7	26
92	Stratifying SLN incidence in intermediate thickness melanoma patients. <i>American Journal of Surgery</i> , 2018, 215, 699-706.	0.9	26
93	Review of diagnostic, prognostic, and predictive biomarkers in melanoma. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 487-493.	1.7	26
94	Recurrence of Melanoma After a Negative Sentinel Node Biopsy: Predictors and Impact of Recurrence Site on Survival. <i>Annals of Surgical Oncology</i> , 2019, 26, 2254-2262.	0.7	26
95	The Surgical Management of Primary and Metastatic Merkel Cell Carcinoma. <i>Current Problems in Cancer</i> , 2010, 34, 77-96.	1.0	25
96	Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 473-482.	2.3	25
97	Lymphatic mapping and sentinel node biopsy: A surgical perspective. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 129-134.	2.5	24
98	A Multicenter Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-arterial Temozolomide for Patients with Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion. <i>Annals of Surgical Oncology</i> , 2015, 22, 287-294.	0.7	24
99	Efficacy of Multiagent Herpes Simplex Virus Amplicon-Mediated Immunotherapy as Adjuvant Treatment for Experimental Hepatic Cancer. <i>Annals of Surgery</i> , 2002, 236, 337-343.	2.1	23
100	Resection of Residual Disease after Isolated Limb Infusion (ILI) Is Equivalent to a Complete Response after ILI-Alone in Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 650-655.	0.7	23
101	Sentinel Lymph Node Mapping in Melanoma in the Twenty-first Century. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 249-260.	0.6	23
102	A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Lovastatin for Various Endpoints of Melanoma Pathobiology. <i>Cancer Prevention Research</i> , 2014, 7, 496-504.	0.7	22
103	The Impact of Smoking on Sentinel Node Metastasis of Primary Cutaneous Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2089-2094.	0.7	22
104	Imaging of Merkel Cell Carcinoma. <i>Current Problems in Cancer</i> , 2010, 34, 65-76.	1.0	21
105	BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma. <i>Melanoma Research</i> , 2016, 26, 83-87.	0.6	21
106	Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. <i>Journal of the American College of Surgeons</i> , 2017, 224, 635-642.	0.2	21
107	Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1). <i>Melanoma Management</i> , 2019, 6, MMT19.	0.1	21
108	Single-institution Outcome Experience Using AlloDerm® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects. <i>American Surgeon</i> , 2013, 79, 476-482.	0.4	20

#	ARTICLE	IF	CITATIONS
109	Quality of life patient-reported outcomes for locally advanced cutaneous melanoma. <i>Melanoma Research</i> , 2018, 28, 134-142.	0.6	20
110	Clinical utilities and biological characteristics of melanoma sentinel lymph nodes. <i>World Journal of Clinical Oncology</i> , 2016, 7, 174.	0.9	20
111	Full-Thickness Grafts Procured from Skin Overlying the Sentinel Lymph Node Basin; Reconstruction of Primary Cutaneous Malignancy Excision Defects. <i>Annals of Surgical Oncology</i> , 2008, 15, 1733-1740.	0.7	19
112	The safety of talimogene laherparepvec for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2016, 16, 1-5.	1.0	19
113	Granular cell tumor—A unique neoplasm of the internal anal sphincter. <i>Diseases of the Colon and Rectum</i> , 2000, 43, 1444-1446.	0.7	18
114	Intralesional therapy for metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2629-2639.	0.9	18
115	Intralesional therapy as a treatment for locoregionally metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 399-408.	1.1	18
116	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 791-801.	0.7	18
117	A Collision of Diseases: Chronic Lymphocytic Leukemia Discovered During Lymph Node Biopsy for Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 1360-1364.	0.7	17
118	Regional therapy in metastatic melanoma: an update on minimally invasive intraarterial isolated limb infusion and percutaneous hepatic perfusion. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1355-1364.	1.5	17
119	Effect of murine liver cell proliferation on herpes viral behavior: Implications for oncolytic viral therapy. <i>Hepatology</i> , 2004, 39, 1525-1532.	3.6	16
120	Chemosaturation with Percutaneous Hepatic Perfusion for Unresectable Isolated Hepatic Metastases from Sarcoma. <i>CardioVascular and Interventional Radiology</i> , 2012, 35, 1480-1487.	0.9	16
121	Engineered oncolytic viruses to treat melanoma: where are we now and what comes next?. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1199-1207.	1.4	16
122	Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging. <i>Annals of Surgery</i> , 2021, 273, 814-820.	2.1	16
123	Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. <i>American Surgeon</i> , 2016, 82, 1109-1116.	0.4	15
124	Intralesional and systemic immunotherapy for metastatic melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1491-1499.	1.4	15
125	Is a Wider Margin (2 cm vs. 1 cm) for a 1.01–2.0 mm Melanoma Necessary?. <i>Annals of Surgical Oncology</i> , 2016, 23, 2336-2342.	0.7	15
126	Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01-4.00 mm): A National Cancer Database study. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 433-440.	0.6	15

#	ARTICLE	IF	CITATIONS
127	Sentinel Lymph Node Biopsy Is Prognostic in Thickest Melanoma Cases and Should Be Performed for Thick Melanomas. <i>Annals of Surgical Oncology</i> , 2021, 28, 1007-1016.	0.7	15
128	A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. <i>Cancer</i> , 2012, 118, 6136-6143.	2.0	14
129	The use of isolated limb infusion in limb threatening extremity sarcomas. <i>International Journal of Hyperthermia</i> , 2013, 29, 1-7.	1.1	14
130	Neo-DREAM study investigating Dacomun for the treatment of clinical stage IIIB/C melanoma. <i>Future Oncology</i> , 2019, 15, 3665-3674.	1.1	14
131	Surveillance of Sentinel Node-Positive Melanoma Patients with Reasons for Exclusion from MSLT-II: Multi-Institutional Propensity Score Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2021, 232, 424-431.	0.2	14
132	Three Cases of Small Bowel Intussusception in Relation to a Rare Lesion: Inflammatory Fibrous Polyps. <i>Digestive Surgery</i> , 2001, 18, 142-146.	0.6	13
133	Multidisciplinary management of special melanoma situations: Oligometastatic disease and bulky nodal sites. <i>Current Oncology Reports</i> , 2007, 9, 417-427.	1.8	13
134	Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck. <i>Head and Neck</i> , 2019, 41, 871-879.	0.9	13
135	Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2021, 28, 6978-6985.	0.7	13
136	Prognostication in Merkel cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 665-667.	1.1	12
137	Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. <i>Journal of the American College of Surgeons</i> , 2016, 222, 702-709.	0.2	12
138	Regional therapies for locoregionally advanced and unresectable melanoma. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 495-502.	1.7	12
139	Completion lymphadenectomy for a positive sentinel node biopsy in melanoma patients is not associated with a survival benefit. <i>Journal of Surgical Oncology</i> , 2019, 119, 1053-1059.	0.8	12
140	The emergence of neoadjuvant therapy in advanced melanoma. <i>Melanoma Management</i> , 2019, 6, MMT27.	0.1	12
141	Surgeon decision-making for management of positive sentinel lymph nodes in the post-Multicenter Selective Lymphadenectomy Trial II era: A survey study. <i>Journal of Surgical Oncology</i> , 2021, 123, 646-653.	0.8	12
142	Phase 1b study of PV-10 and anti-PD-1 in advanced cutaneous melanoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 9559-9559.	0.8	12
143	Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2007, 5, 483-90.	0.3	12
144	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. <i>European Journal of Cancer</i> , 2022, 169, 210-222.	1.3	12

#	ARTICLE	IF	CITATIONS
145	Dermal melanoma: A report on prognosis, outcomes, and the utility of sentinel lymph node biopsy. <i>Journal of Surgical Oncology</i> , 2016, 113, 98-102.	0.8	11
146	Microsatellitosis in Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 33-41.	0.7	11
147	Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 86-95.	1.5	11
148	An evaluation of encorafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 155-161.	0.9	11
149	Sentinel lymph node biopsy in melanoma: beyond histologic factors. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 29-38.	1.7	11
150	A comparison between patients with gastrointestinal stromal tumours diagnosed with isolated liver metastases and liver metastases plus sarcomatosis. <i>Hpb</i> , 2013, 15, 655-660.	0.1	10
151	Analysis of Tumor Mitotic Rate in Thin Metastatic Melanomas Compared With Thin Melanomas Without Metastasis Using Both the Hematoxylin and Eosin and Anti-phosphohistone 3 IHC Stain. <i>American Journal of Dermatopathology</i> , 2014, 36, 64-67.	0.3	10
152	Current approaches to cutaneous sarcomas: Dermatofibrosarcoma protuberans and cutaneous leiomyosarcoma. <i>Current Problems in Cancer</i> , 2015, 39, 248-257.	1.0	10
153	Implications of staged reconstruction and adjuvant brachytherapy in the treatment of recurrent soft tissue sarcoma. <i>Brachytherapy</i> , 2016, 15, 495-503.	0.2	10
154	Treatment of Head and Neck Melanoma In Situ With Staged Contoured Marginal Excisions. <i>Annals of Plastic Surgery</i> , 2017, 78, 663-667.	0.5	10
155	Chemosaturation with Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases. <i>Cancer Control</i> , 2017, 24, 96-101.	0.7	10
156	International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1420-1429.	0.7	10
157	Single-institution outcome experience using AlloDerm® as temporary coverage or definitive reconstruction for cutaneous and soft tissue malignancy defects. <i>American Surgeon</i> , 2013, 79, 476-82.	0.4	10
158	Isolated hepatic perfusion for metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 383-388.	0.8	9
159	Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 469-473.	1.5	9
160	Factors predicting survival in thick melanoma: Do all thick melanomas have the same prognosis?. <i>Surgery</i> , 2020, 168, 518-526.	1.0	9
161	Talimogene laherparepvec: overview, combination therapy and current practices. <i>Melanoma Management</i> , 2016, 3, 267-272.	0.1	8
162	Selecting Patients With Thin Melanoma for Sentinel Lymph Node Biopsy—This Time It’s Personal. <i>JAMA Dermatology</i> , 2017, 153, 857.	2.0	8

#	ARTICLE	IF	CITATIONS
163	An evaluation of talimogene laherparepvec for the treatment of melanoma. Expert Opinion on Biological Therapy, 2020, 20, 9-14.	1.4	8
164	Perioperative Outcomes of Melanoma Patients Undergoing Surgery After Receiving Immunotherapy or Targeted Therapy. World Journal of Surgery, 2020, 44, 1283-1293.	0.8	8
165	Factors predicting toxicity and response following isolated limb infusion for melanoma: An international multi-centre study. European Journal of Surgical Oncology, 2020, 46, 2140-2146.	0.5	8
166	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. Annals of Surgical Oncology, 2020, 27, 5107-5118.	0.7	8
167	Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era. Annals of Surgical Oncology, 2021, 28, 3512-3521.	0.7	8
168	Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma. Annals of Surgical Oncology, 2021, 28, 6995-7003.	0.7	8
169	Profound proliferating angiolymphoid hyperplasia with eosinophilia of pregnancy mimicking angiosarcoma. Cutis, 2011, 88, 122-8.	0.4	8
170	Proper Margins of Excision in Dermatofibrosarcoma Protuberans: Wide or Narrow?. Annals of Surgical Oncology, 2008, 15, 2614-2616.	0.7	7
171	Minimally invasive intra-arterial regional therapy for metastatic melanoma: isolated limb infusion and percutaneous hepatic perfusion. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1383-1394.	1.5	7
172	Unanswered Questions in the Management of Stage I-III Merkel Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 425-431.	2.3	7
173	Intraperitoneal Rosai-Dorfman disease associated with clear cell sarcoma: first case report. Pathology, 2016, 48, 742-744.	0.3	7
174	Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience. Pathology and Oncology Research, 2020, 26, 239-244.	0.9	7
175	Isolated limb infusion: Institutional protocol and implementation. Journal of Surgical Oncology, 2020, 122, 99-105.	0.8	7
176	Regression is significantly associated with outcomes for patients with melanoma. Surgery, 2021, 170, 1487-1494.	1.0	7
177	Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. Cancer Control, 2020, 27, 107327482098301.	0.7	7
178	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis. Cancer Control, 2021, 28, 107327482110535.	0.7	7
179	Resection of Gastrointestinal Metastases in Stage IV Melanoma: Correlation with Outcomes. American Surgeon, 2016, 82, 1109-1116.	0.4	7
180	Cytoreductive Surgery for Melanoma. Surgical Oncology Clinics of North America, 2007, 16, 683-693.	0.6	6

#	ARTICLE	IF	CITATIONS
181	MSLT-1â€™ putting sentinel lymph node biopsy into context. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 246-248.	12.5	6
182	Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. <i>Melanoma Management</i> , 2019, 6, MMT33.	0.1	6
183	Robotic-Assisted Pelvic Lymphadenectomy for Metastatic Melanoma Results in Durable Oncologic Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 196-202.	0.7	6
184	Overestimation of Risk for Sentinel Lymph Node Metastasis in a Nomogram for T1 Melanomas. <i>Journal of Clinical Oncology</i> , 2020, 38, 3234-3235.	0.8	6
185	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 687-701.	1.1	6
186	In-transit metastatic cutaneous melanoma: current management and future directions. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 201-211.	1.7	6
187	Laparoscopic Appendectomy for Crohn's Disease of the Appendix Presenting as Acute Appendicitis. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2001, 11, 255-258.	0.5	5
188	Isolated Regional Therapy for Advanced Extremity Soft Tissue Sarcomas. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 287-299.	0.6	5
189	Management of intussusception in patients with melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 897-902.	0.8	5
190	Intra-arterial perfusion-based therapies for regionally metastatic cutaneous and uveal melanoma. <i>Melanoma Management</i> , 2019, 6, MMT26.	0.1	5
191	Management of Locoregionally Advanced Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 109-125.	0.5	5
192	The Devilâ€™s in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 5259-5266.	0.7	5
193	Metastatic melanoma patientsâ€™ sensitivity to ipilimumab cannot be predicted by tumor characteristics. <i>International Journal of Surgery Oncology</i> , 2017, 2, e43-e43.	0.2	5
194	Local and Recurrent Regional Metastases of Melanoma. , 2020, , 705-737.		5
195	External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 1637-1644.	0.7	5
196	Is There a Relationship Between TILs and Regression in Melanoma?. <i>Annals of Surgical Oncology</i> , 2022, 29, 2854-2866.	0.7	5
197	The Role of Ultrasound in the Surgical Management of Patients Diagnosed with Ductal Carcinoma in Situ of the Breast. <i>Breast Journal</i> , 2006, 12, 212-215.	0.4	4
198	^{99m} Tc-tilmanocept for lymphoscintigraphy. <i>Imaging in Medicine</i> , 2013, 5, 119-125.	0.0	4

#	ARTICLE	IF	CITATIONS
199	Is pelvic sentinel node biopsy necessary for lower extremity and trunk melanomas?. American Journal of Surgery, 2017, 213, 921-925.	0.9	4
200	Metastasectomy for Abdominal Visceral Oligometastatic Melanoma. JAMA Surgery, 2017, 152, 678.	2.2	4
201	Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. Melanoma Management, 2018, 5, MMT02.	0.1	4
202	The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. Annals of Surgical Oncology, 2020, 27, 35-42.	0.7	4
203	Improving clinical outcomes with pembrolizumab in patients with advanced melanoma. Chinese Clinical Oncology, 2017, 6, 2-2.	0.4	4
204	Is the presence of tumor-infiltrating lymphocytes predictive of outcomes in patients with melanoma?. Cancer, 2022, 128, 1418-1428.	2.0	4
205	Efficacy of Neoadjuvant Intratumoral DArleukin/Fibromun (L19IL2 + L19TNF) in Patients with Clinical Stage IIIB/C Melanoma (Neo-DREAM). Annals of Surgical Oncology, 2022, 29, 3377-3378.	0.7	4
206	Commentary on pharmacotherapy of regional melanoma therapy. Expert Opinion on Pharmacotherapy, 2010, 11, 1-3.	0.9	3
207	Genetic Testing in the Multidisciplinary Management of Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 779-793.	0.6	3
208	Advances in the management of genitourinary melanomas. AME Medical Journal, 0, 4, 41-41.	0.4	3
209	Observational study of talimogene laherparepvec use in the anti-PD-1 era for melanoma in the US (COSMUS-2). Melanoma Management, 2020, 7, MMT41.	0.1	3
210	Molecular Aspects of the Isolated Limb Infusion Procedure. Biomedicines, 2021, 9, 163.	1.4	3
211	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. Expert Review of Precision Medicine and Drug Development, 2021, 6, 19-29.	0.4	3
212	Current standards of surgical management in primary melanoma. Italian Journal of Dermatology and Venereology, 2018, 153, 56-67.	0.1	3
213	ASO Visual Abstract: Talimogene Laherparepvec (T-VEC) for Treatment of Advanced Locoregional Melanoma after Failure of Immunotherapy: An International Multi-institutional Experience. Annals of Surgical Oncology, 2021, 29, 804.	0.7	3
214	The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials. Expert Opinion on Investigational Drugs, 2022, 31, 95-104.	1.9	3
215	Introduction: Novel Frontiers in Cancer Metastasis. Clinical and Experimental Metastasis, 2022, 39, 3-5.	1.7	3
216	Isolated limb infusion for melanoma: a less morbid alternative to hyperthermic isolated limb perfusion in the US. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1033-1037.	1.5	2

#	ARTICLE	IF	CITATIONS
217	Primary Tumor Thickness as a Prognostic Factor in Merkel Cell Carcinoma: The Next Big Thing?. Annals of Surgical Oncology, 2012, 19, 3307-3309.	0.7	2
218	Recent Advances in the Treatment of Melanoma. Cancer Control, 2013, 20, 244-245.	0.7	2
219	Editorial. Clinical and Experimental Metastasis, 2018, 35, 359-360.	1.7	2
220	Future perspectives: cancer metastases. Clinical and Experimental Metastasis, 2018, 35, 559-561.	1.7	2
221	ASO Author Reflection: Isolated Limb Infusion for Locally Advanced Melanoma in the Extremely Old Patient is Safe and Effective. Annals of Surgical Oncology, 2020, 27, 1430-1431.	0.7	2
222	ASO Visual Abstract: Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection. Annals of Surgical Oncology, 2021, 28, 678-679.	0.7	2
223	Letter Regarding Editorial by Samuel Zagarella. American Journal of Dermatopathology, 2021, 43, 539-541.	0.3	2
224	Editorial: Novel Frontiers in Cancer Metastasis. Clinical and Experimental Metastasis, 2022, 39, 1-1.	1.7	2
225	An update on local and systemic therapies for nonmelanoma skin cancer. Expert Review of Anticancer Therapy, 2022, 22, 479-489.	1.1	2
226	Melanoma: Promising New Discoveries and Treatment Modalities for Difficult Clinical Scenarios. Cancer Control, 2008, 15, 192-194.	0.7	1
227	Predictors of outcome in patients with recurrent gastrointestinal stromal tumors. Journal of the American College of Surgeons, 2011, 213, S131-S132.	0.2	1
228	ASO Author Reflections: Resection Margins in Merkel Cell Carcinoma: Is a 1cm Margin Wide Enough?. Annals of Surgical Oncology, 2018, 25, 901-901.	0.7	1
229	ASO Author Reflections: Return to Isolated Limb Infusion for In-Transit Melanoma. Annals of Surgical Oncology, 2020, 27, 5119-5120.	0.7	1
230	Developments in therapy for brain metastases in melanoma patients. Expert Opinion on Pharmacotherapy, 2021, 22, 1443-1453.	0.9	1
231	The Surgeons'™ Role When Systemic Therapies Fail in Metastatic Melanoma: The Salvage Metastasectomy. Annals of Surgical Oncology, 2021, 28, 5801-5802.	0.7	1
232	Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence-free survival. Journal of Surgical Oncology, 2022, 125, 229-238.	0.8	1
233	Isolated Limb Infusion for Melanoma. , 2020, , 827-850.		1
234	Infusion Technique. , 2020, , 357-366.		1

#	ARTICLE	IF	CITATIONS
235	Retrospective analysis of patients with sentinel lymph node (SLN) positive melanoma (MEL) who received adjuvant nivolumab (NIVO) without completion lymph node dissection (CLND).. Journal of Clinical Oncology, 2019, 37, 9590-9590.	0.8	1
236	Local and Recurrent Regional Metastases of Melanoma. , 2019, , 1-33.		1
237	Ten Best Readings Relating to Melanoma. Cancer Control, 2008, 15, 271-271.	0.7	0
238	Melanoma: Promising New Discoveries and Treatment Modalities for Difficult Clinical Scenarios â€” Part II. Cancer Control, 2009, 16, 196-197.	0.7	0
239	Surgically Unresectable Regional Melanoma Metastases in a Patient With Renal Failure and Peripheral Vascular Disease: Are There Safe and Potentially Effective Treatments?. Seminars in Oncology, 2010, 37, 303-313.	0.8	0
240	Strategies for Solutions in Sarcoma Management. Cancer Control, 2011, 18, 148-149.	0.7	0
241	Differential gene expression in liposarcoma: A biologic basis for clinically aggressive behavior?. Journal of the American College of Surgeons, 2012, 215, S122-S123.	0.2	0
242	Interclavicular Stabilization With the Synthes Sternal Fixation System After Radical Manubriectomy: Report of 3 Cases. Chest, 2014, 145, 35A.	0.4	0
243	Art, Science, and Personalized Cancer Care through Regional Therapeutics. Cancer Control, 2016, 23, 3-4.	0.7	0
244	Pre-SN Ultrasound-FNAC for Lymph Node Metastases in Melanoma Patients: A Reply. Annals of Surgical Oncology, 2017, 24, 663-664.	0.7	0
245	Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma. Cancer, 2018, 124, 2254-2255.	2.0	0
246	Considerations for Nonmelanoma Skin Cancer: Clinical Presentation. , 2018, , 75-87.		0
247	Management of Locally and Regionally Recurrent Melanoma. , 2018, , 1-20.		0
248	Management of Locally and Regionally Recurrent Melanoma. , 2019, , 515-534.		0
249	Re-biopsy of partially sampled thin melanoma impacts sentinel lymph node sampling as well as surgical margins. Melanoma Management, 2019, 6, MMT17.	0.1	0
250	ASO Author Reflections: International Experience of Isolated Limb Infusion for Melanoma Shows Durable Response. Annals of Surgical Oncology, 2019, 26, 2495-2496.	0.7	0
251	Locoregional melanoma: identifying optimal care in a rapidly changing landscape. Melanoma Management, 2019, 6, MMT22.	0.1	0
252	ASO Author Reflections: Robotic Pelvic Lymph Node Dissection for Metastatic Melanomaâ€”A Minimally Invasive Approach to a Difficult Problem. Annals of Surgical Oncology, 2020, 27, 203-204.	0.7	0

#	ARTICLE	IF	CITATIONS
253	ASO Author Reflections: T-VEC as Salvage for Progression of Locoregionally Metastatic Melanoma After Failure of Immunotherapy. <i>Annals of Surgical Oncology</i> , 2021, 29, 802.	0.7	0
254	Imaging of Merkel Cell Carcinoma. <i>Molecular Medicine and Medicinal</i> , 2010, , 159-180.	0.4	0
255	New Prognostic Factors in Merkel Cell Carcinoma. <i>Molecular Medicine and Medicinal</i> , 2010, , 143-158.	0.4	0
256	Isolated Limb Infusion for Melanoma. , 2019, , 1-24.		0
257	Isolated Limb Perfusion and Infusion in the Management of In-Transit Melanoma of the Extremities: Modern Data Affecting Practice. , 2020, , 379-394.		0
258	Intralesional Therapies: Oncolytic Viral Therapies, Immunostimulants. , 2020, , 439-450.		0
259	Clinical Insignificance of Percutaneous Hepatic Perfusion-Associated Troponin Elevation. <i>Journal of the American College of Surgeons</i> , 2021, 233, S245.	0.2	0
260	ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 1647.	0.7	0
261	ASO Author Reflections: Is There a Relationship Between TIL and Regression in Melanoma?. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
262	Future perspectives: Novel Frontiers in Cancer Metastasis. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 255.	1.7	0
263	Local and regional therapy for primary and locally recurrent melanoma. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 246-260.	0.3	0
264	Dedication to late Dale Han, MD. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 257-257.	1.7	0
265	Patterns of Recurrence and Prognosis in Pathologic Stage I and II Merkel Cell Carcinoma: A multi-center, retrospective cohort analysis. <i>Journal of the American Academy of Dermatology</i> , 2022, , .	0.6	0